HDAC inhibitors have emerged as promising therapeutic agents in the field of epigenetics, offering new avenues for the treatment of cancer, neurological disorders, viral infection, multiple sclerosis and other diseases [71]. Here, HDAC9 is linked to viral infectious disease.